Good morning, everyone, and how are you today? We are doing just fine, despite some unexpected tech problems. So please excuse the late delivery. Unfortunately, cups of stimulation do not overcome every challenge. Nonetheless, we are persevering and happy to provide a few items of interest for what we hope will be a smooth ride today. So, time to get cracking. We hope you have a productive day and, of course, stay safe — and wear a mask.…

A White House decision to halt release of new standards for emergency authorization of a Covid-19 vaccine came after officials close to President Trump told the Food and Drug Administration the pharmaceutical industry objected to tougher requirements, Politico reports. The White House cited the opposition as a chief reason for blocking the guidelines, which aim to hold vaccines to a higher bar for safety and effectiveness and would likely push any authorization beyond Election Day. FDA officials suspect the White House is exaggerating the level of industry opposition to justify vetoing release of guidelines that might undercut Trump’s campaign message that the pandemic is close to being over.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy